Jan 21, 2021
Heron Therapeutics Announces Publication of Results from EPOCH 1 Follow-On Study of HTX-011 in Patients Undergoing Bunionectomy Surgery
Nov 05, 2020
Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2020 and Highlights Recent Corporate Updates
Sep 16, 2020
Heron Therapeutics Announces Publication of Results from EPOCH 2 Follow-On Study, a Phase 2b Study of HTX-011 in Patients Undergoing Hernia Repair Surgery
Sep 11, 2020
Heron Therapeutics to Present at Cantor Virtual Global Healthcare Conference
Sep 08, 2020
Heron Therapeutics Announces Successful Outcome of FDA Type A Meeting to Discuss HTX-011 for the Management of Postoperative Pain
Aug 05, 2020
Heron Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2020 and Highlights Recent Corporate Updates
Jul 24, 2020
Heron Therapeutics Receives Positive CHMP Opinion for ZYNRELEF(TM) (HTX-011) for the Management of Postoperative Pain
Jul 16, 2020
Heron Therapeutics Announces Initiation of Phase 2 Clinical Study of CINVANTI® for the Treatment of COVID-19
Jun 29, 2020
Heron Therapeutics Receives Complete Response Letter for HTX-011 for the Management of Postoperative Pain
Jun 04, 2020
Heron Therapeutics Announces Publication of Results from Study 209, a Phase 2b Study of HTX-011 in Patients Undergoing Total Knee Arthroplasty
May 18, 2020
Heron Therapeutics Announces Initiation of Phase 1b/2 Clinical Study of HTX-034 for the Treatment of Postoperative Pain
Mar 02, 2020
Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2019 and Highlights Recent Corporate Updates
Feb 19, 2020
Heron Therapeutics Announces FDA Extension of Review Period for NDA for HTX-011 for the Management of Postoperative Pain
Feb 18, 2020
Heron Therapeutics to Present at the 9th Annual SVB Leerink Global Healthcare Conference
Jan 13, 2020
Heron Therapeutics Highlights Progress in Pain Management and CINV Franchises
Dec 16, 2019
Heron Therapeutics Announces Publication of the Mechanism of Action Data for HTX-011, a Dual-Acting Local Anesthetic Being Developed for Management of Postoperative Pain
Dec 03, 2019
Health Canada Grants Priority Review Status for Heron Therapeutics' New Drug Submission for HTX-011 for Management of Postoperative Pain
Nov 14, 2019
Heron Therapeutics to Present at the Jefferies London Healthcare Conference
Nov 12, 2019
Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2019 and Highlights Recent Corporate Updates
Oct 28, 2019
Heron Therapeutics Announces FDA Acceptance of New Drug Application Resubmission for HTX-011 for Management of Postoperative Pain